Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
Clinical trial NCT07630649 · RECRUITING
Trial details
- NCT number
- NCT07630649
- Sponsor
- Adverum Biotechnologies, Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-02
- Primary completion
- 2031-06-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.